Universal screening for gestational diabetes by DIPSI test by Dr.Preksha
prekshajain5055
8,576 views
37 slides
Aug 05, 2014
Slide 1 of 37
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
About This Presentation
pilot study, gestational diabetes mellitus, screening by post glucose blood sugar DIPSI test fetal and maternal outcome
Size: 5.8 MB
Language: en
Added: Aug 05, 2014
Slides: 37 pages
Slide Content
UNIVERSAL SCREENING OF ANTENATAL WOMEN FOR GESTATIONAL DIABETES MELLITUS AND THEIR FETOMATERNAL OUTCOMES Dr. Preksha Jain, Junior resident Dr. Sunita Ghike , Professor Dept. of ObGy , Nkp salve institute of Medical Sciences
Motherhood is a joy of living life once again
DEFINITION Gestational diabetes mellitus (GDM) is carbohydrate intolerance with recognition or onset first time during pregnancy, irrespective of the treatment with diet or insulin.
One of major causes of complications during pregnancy Good glycemic control-improves perinatal outcome
IMPORTANCE OF GDM 2 GENERATIONS AT RISK TYPE 2 DM CHILDHOOD OBESITY TYPE 2 DM
In the Indian context, there is 11 fold increased risk of developing glucose intolerance during pregnancy compared to Caucasian women . 16.55% prevalence of GDM Urban 17.8% Rural 9.91%.
EFFECT ON PREGNANCY Insulin resistance : Production of placental HPL. Increased production of cortisol, estriol , progesterone . Increased insulin destruction by kidney and placenta. Increased lipolysis : F or her caloric needs and saves glucose for fetal needs. Changes in gluconeogenesis : F etus uses preferentially alanine and other amino acids and deprives the mother of a major gluconeogenic source.
Hormonal events during early Pregnancy Early pregnancy Estrogen Progesterone Pancreatic B-cell hyperplasia Insulin secretion Peripheral utilization of glucose Maternal FBS Hepatic glucose production Glycogen storage
Hormonal events during mid pregnancy Mid-trimester pregnancy HPL Cortisol Prolactin Progesterone Estrogen Insulin resistance in peripheral tissues
COMPLICATIONS NICU admission
SCREENING Selective & Universal Selective screening approach will miss a proportion of GDM, 30 %. 45% unscreened.
Various screening tests Blood tests Fasting blood glucose (FBG) test DIPSI 75gm glucose Glycosylated hemoglobin
AIMS & OBJECTIVES The objective is to estimate PGBS in antenatal women and follow up them till delivery for fetomaternal outcomes . To screen for GDM & GGI as early as possible. Determine f etomaternal outcome.
MATERIAL & METHODS STUDY DESIGN : Prospective Longitudinal Observational Time bound hospital based study . DURATION: 07 months. SETTINGS: Dept. of ObGy , NKP Salve Institute Of Medical Sciences Nagpur STUDY POPULATION: Women attending antenatal OPD. SAMPLE SIZE : 400 SELECTION: Consecutive Institutional Ethical committee permission
INCLUSION CRITERIA: Singleton pregnancies . Patients willing to comply . Patients willing to deliver at LMH EXCLUSION CRITERIA : Multiple pregnancies . History of previous GDM . Patients not willing for any intervention . Patients not willing to deliver at LMH
Demographic data, Medical, Obstetric & Surgical history, antepartum, intra partum & postpartum data was collected. Analysis was done regarding number of patients with GDM & GGI, distribution according to age, parity & their fetomaternal outcomes . Statistical evaluation was done.
OUTCOME MEASURES MATERNAL Age Parity Preeclampsia/PIH Polyhydramnios BOH Mode of delivery FETAL Preterm IUGR Baby weight NICU Admissions Respiratory distress Perinatal mortality
METHODOLOGY Detailed history, consent, examination done DIPSI TEST was done 75gm of glucose dissolved in 200ml of water, consumed over period of 15min (regardless of day or time of last meal) Venous blood samples taken at 2hrs.
TOTAL PATIENTS SCREENED & DISTRIBUTION ACCORDING TO INTOLERANCE GGI GDM OVERT 54(13.5%) 37(9.25%) 6(1.5%) TOTAL SCREENED TOTAL NORMAL DERANGED PGBS 400 303 97(24.25%) 13.5% patients had normal PGBS in early trimester but later diagnosed with GDM by repeat screening .
AGE DISTRIBUTION TABLE AGE GGI GDM OVERT <19 8% 8.3% 0% 20-25 13.52% 8.6% 0% 26-30 12% 10.93% 2.3% >31 31% 12.5% 6.25% Advancing age was associated with increasing trend of GGI & GDM
Distribution by gravidity Prevalence of glucose intolerance increased with gravidity
Gestational Age GGI GDM OVERT <24wk 6.1% 2.06% 24-32 11.34% 8.24% 1.03% >32 41.23% 27.80% 5.10% Increased incidence was noted in third trimester because maximum patients presented in third trimester
Maternal Complications NORMAL GDM+GGI PIH 14% 18.55% POLY 2.3% 3% CPD 0.3% 2.06% PROM 2.6% 5.1% BOH 20.46% 24.74%
Fetal Complications
Fetal Complications NORMAL GDM+GGI RESP DISTRESS 7.9% 9.2% PRETERM 2.3% 3% IUGR 5.9% 6.1% NICU 4.9% 6% PERINATAL MORTALITY 1.05% 1.09% CONG ANOMALY 0.3% 1.03% MOST COMMAN COMPLICATION FOUND TO BE RESPIRATORY DISTRESS
HbA1c HbA1c% GDM & GGI < 5.7 4.10% 5.7-6.1 1% >6.1 8.20% MAXIMUM PATIENTS WITH GDM HAD HbA1c MORE THAN 6.1%
MODE OF DELIVERY NORMAL GDM+GGI NVD 21.10% 19.5% LSCS 32% 44.5% INSTRUMENTAL 1.9% 1.3% S&E 0.6% 1.03% INCIDENCE OF CESAREAN SECTION WAS MAXIMUM AMONG GDM PATIENTS
SUMMARY Out of 400 antenatal women, 54 had GGI (13.5%) 37 had GDM (9.25 %) according to screening by DIPSI Prevalence rate of GDM was 9.25% which was significant Advancing age was associated with increasing trend of GGI & GDM
Pregnancy complications noted in the present study in patients with GDM were -- PIH in 18.55%,Poly in 3%, PROM in 5%, CPD in 2.06% Operative deliveries were found more in GDM patients 44.5% Fetal complications noted were 9.2% of neonates had respiratory distress, 6% had NICU admissions Perinatal mortality rate 1.09% were high in GDM patients 8.3% patients managed by insulin & diet
ROLE OF OBSTETRICIAN PRIMARY PREVENTION: Obesity, PCOS- lifestyle modification SECONDARY PREVENTION: GDM screening & care TERTIARY PREVENTION: Future long term complication
TAKE HOME MESSAGE GDM continues to be an important obstetrical condition with significant feto maternal morbidity. This study thus recommends screening of all antenatal women for GGI & GDM as early as possible & proper management to ameliorate morbidity & mortality associated with it.